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ABSTRACT
The Recommendations of the Polish Society of Oncological Gynaecology offers evidence-based advice on the 
care and treatment of women with ovarian cancer and low malignant potential/borderline tumour.
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Aetiology [1]
Over 95% of malignant tumours of the ovary are of 
epithelial origin. The most important risk factors for the 
development of ovarian cancer include the following:
 — carriage of mutation of BRCA1 and BRCA2 genes 
(concerns up to 13% of all ovarian cancer cases);
 — syndromes of hereditary cancer of breast and ovary;
 — familial occurrence of hereditary non-polyposis co-
lon cancer (Lynch syndrome — early non-polyposis 
colorectal cancer, endometrial cancer, proximal di-
gestive tract cancer, urothelial cancer of the urethra);
 — childlessness, long-lasting stimulation of ovulation, 
ineffective attempts at in vitro fertilisation (IVF).
Hormonal contraceptive drugs, oviducts’ occlusion, 
bilateral salpingo-oophorectomy, hysterectomy and 
breastfeeding decrease the risk of ovarian cancer de-
velopment.
Screening [2]
Currently there are no unavailable screening 
tests detecting ovarian cancer, also in patients dur-
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ing follow-up due to known mutation of BRCA genes 
[3]. Detection of an ovarian cancer at an early stage 
still occurs in a relatively small proportion of women 
(20–30%). In the remaining patients (nearly 70%), the 
disease is detected at higher clinical stages (III and IV). 
Prevention
Due to considerable risk of development of ovar-
ian cancer in carriers of mutation of BRCA1 and 
BRCA2 genes, bilateral adnexectomy after termination 
of procreative activity is currently recommended [4]. 
According to recently published reports suggesting that 
the majority of ovarian cancers derive from fimbriae of 
the oviduct, preventive oophorectomy should be also 
considered in women at low risk after meeting mater-
nal goals and after menopause, who have undergone 
non-oncological surgical procedures [5, 6].
Diagnostic studies 
While there are no clinical signs typical for ovarian 
cancer, most patients complain of non-specific dyspep-
tic ailments approximately one year prior to diagnosis 
of the tumour [7]. In early clinical stages (25–30% of 
cases) there may be a palpable adnexal tumour pre-
sent. Patients with late stage disease (about 70% of the 
cases), apart from uni- or bilateral adnexal tumour, may 
present with ascites and/or hydrothorax and elevated 
CA-125 antigen levels. Some patients may have normal 
or only slightly enlarged ovaries in spite of cancer spread 
within the abdominal cavity. 
In all cases of ovarian cancer we recommend calcu-
lating the risk of malignancy index (RMI) (Appendix 1) 
and the ROMA (Risk of Ovarian Malignancy Algo-
rithm) test is indicated.
In case of RMI > 200 points or when the value 
of the ROMA test suggests that patients belong to 
a high-risk group it is recommended to refer the patients 
to a specialised centre with experience in ovarian cancer 
treatment [1, 8].
Diagnosis
Diagnosis of ovarian cancer relies on histologi-
cal examination of tissue specimens obtained during 
the primary surgical procedure. In exceptional cases, 
diagnosis is possible based on analysis of peritoneal 
or pleural fluid obtained by biopsy, lymph nodes, or 
a metastasis to the liver.
In each case, the following should be determined:
 — histological type;
 — histological differentiation grade (G1, G2, or G3). 
At present, subdividing the most common serous 
type of ovarian cancer into high grade and low grade 
seems to be justified [9].
Assessment of the incidence of gene mutations 
predisposing to higher risk of ovarian cancer
Due to their high importance both in the prevention 
and treatment of ovarian cancer, genetic consultation 
and assessment of the mutation carriage of BRCA1 and 
BRCA2 genes should be performed in all patients with 
this type of cancer. Detection of mutated status has 
a prognostic as well as predictive value and also indicates 
the high risk of breast cancer. It allows encompassing 
healthy female carriers in the patient’s family in ap-
propriate healthcare and activities decreasing the risk 
of breast cancer and ovarian cancer development [10].
Staging of the tumour 
The clinical stage of a tumour of the ovary is de-
termined in surgical-pathomorphological grades (it 
concerns epithelial and non-epithelial tumours). The 
current FIGO (Fédération internationale de gynécologie 
et d’obstétrique) classification of ovarian cancer was 
introduced in 2014 [11] (Appendix 2).
Treatment 
The cornerstone of primary treatment of newly 
diagnosed ovarian cancer is combined management 
including surgical treatment and chemotherapy. 
Surgical treatment 
The aim of primary surgical treatment:
 — confirmation of ovarian cancer diagnosis;
 — determination of clinical stage;
 — total, alternatively optimal, cytoreduction of the 
tumour. 
The scope of primary cytoreductive procedure and 
adjuvant therapy depends mainly on the clinical stage 
of the tumour.
Cancer macroscopically limited to the genital tract
After inspection of the abdominal cavity excluding 
gross extrapelvic lesions, surgical treatment includes:
 — obtaining fluid and lavage fluid for cytological study 
(before initiating of surgical procedures);
 — bilateral salpingo-oophorectomy;
 — radical hysterectomy;
 — excision of the greater omentum;
 — obtaining smears and random tissue samples from 
the peritoneum;
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 — pelvic and aortal lymphadenectomy;
 — appendectomy — mandatory in cases of mucous 
histology [12].
In young women who wish to preserve fertility, with 
cancer lesion limited to one ovary, without capsular in-
filtration or peritoneal adhesions, an acceptable option 
is to spare the uterus and contralateral ovary [13, 14].
Other cases of ovarian cancer 
The primary aim of surgery is total cytoreduction, 
e.g. lack of gross residual tumour in the abdominal 
cavity. All visible lesions should be removed (Table 1). 
In case of a lack of the possibility to meet this goal, op-
timal cytoreduction should be achieved (with residual 
lesions of diameter < 1 cm). If such a solution is also not 
feasible, the scope of the operation should be limited to 
excision of the affected omentum, or big adnexal masses, 
in order to reduce perioperative complication and in-
troduce chemotherapy as soon as possible. Suboptimal 
procedures significantly shorten the time to progression 
and overall survival time [15]. The patients with poor 
prognosis of at least optimal cytoreduction due to dis-
ease burden should be identified. They are candidates 
for neoadjuvant chemotherapy.
Excision of enlarged retroperitoneal lymph nodes 
is an additional part of the cytoreductive procedure.
The main reason that makes complete cytoreduction 
impossible is infiltration of the mesentery and lesions 
in the hepatic hilus. Mutilating procedures, e.g. total 
colectomy, should be avoided because they may reduce 
the patient’s chances for further chemotherapy.
Validity of systemic pelvic and periaortic lym-
phadenectomy of normal-appearing lymph nodes 
in the case of residual tumour left in the abdominal 
cavity is currently questioned. On the other hand, 
the rationale for systemic pelvic and periaortic lym-
phadenectomy of normal-appearing lymph nodes in 
the case of lack of residual tumour in the abdominal 
cavity is currently a subject of the prospective clinical 
trial AGO – LION.
Conducting procedures determining the clinical 
stage (obtaining the fluid, biopsy of peritoneum, smears) 
during cytoreductive operations of advanced ovarian 
cancer is unfounded.
Delayed surgery 
If complete cytoreduction is impossible, in some pa-
tients a delayed surgery (interval debulking surgery, IDS; 
interval cytoreductive surgery) should be considered after 
three cycles of chemotherapy, followed by continued 
chemotherapy (up to a total number of scheduled cycles). 
Such a protocol is recommended in the case of a favour-
able therapeutic response after chemotherapy [16].
Secondary cytoreductive surgery 
Effectiveness of secondary cytoreductive surgery 
performed after completion of first-line chemo-
therapy in the case of cancer progression has not 
been confirmed in randomised clinical trials, and 
available data come from individual non-randomised 
studies [17].
Second-look operation 
An operation performed to verify therapeutic 
response (second-look operation) does not affect 
prolongation of survival time and is currently not 
recommended in clinical practice. 
Chemotherapy
Most patients with ovarian cancer are candidates 
for systemic chemotherapy. Desisting from postopera-
tive chemotherapy is possible only in a small group of 
patients of stage IA or IB (according to FIGO) G1, 
G2 (good prognosis group) after complete surgical de-
termination of the clinical stage (full scope of surgery 
with pelvic and periaortal lymphadenectomy). In other 
patients with stage I disease the cornerstone of first-line 
treatment is a combination of platinum (carboplatin or 
cisplatin) and taxoid (paclitaxel) administered intrave-
nously in 21-day cycles. The whole treatment should 
consist of 3 to 6 cycles. Both mentioned chemotherapy 
schedules offer an identical efficacy. However, carbo-
platin is better tolerated and more convenient to use. 
Use of paclitaxel requires premedication with steroids, 
H2-receptor blockers, and antihistamines. In patients 
with late stage ovarian cancer (IIB–IV according to 
FIGO) standard postoperative chemotherapy usually 
consists of six cycles. 
Table 1. Type of peritonectomy and the scope of resection during cytoreductive therapy of ovarian cancer
Type of peritonectomy Scope of resection 
Pelvic peritonectomy Uterus, ovaries, sigmoid colon
Left upper quadrant peritonectomy Greater omentum and spleen
Right upper quadrant peritonectomy Tumour infiltrating Glisson’s capsule of the liver
Anterior parietal peritonectomy Old abdominal scars, umbilicus and epigastric fatty tissue
Omental bursectomy Gall bladder, lesser omentum
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Standard protocol includes paclitaxel at a dose of 
175 mg/m2 in a three-hour infusion and carboplatin at 
a dose according to AUC 6 (range 5–7) in a 30-minute 
infusion [18]. When using a cisplatin-based protocol, the 
treatment cycle is longer due to a 24-hours long adminis-
tration of paclitaxel and necessary hydration before and 
after administration of cisplatin on the next day [19].
In the group of patients at stage II–IV with re-
sidual tumour with diameter of less than 1 cm after 
cytoreduction, the therapy of choice is intraperitoneal 
administration of chemotherapy combined with sys-
temic treatment [20]. Paclitaxel-based chemotherapy 
administered every seven days at a dose of 80 mg/m2 is 
an alternative to treatment every 21 days. During this 
schedule the risk of haematological toxicities is high and 
a significant percentage of patients (37%) require use 
of colony stimulating factors (CSFs) [21]. Based on the 
results of a phase III study MITO-7 it can be stated that 
a combination of paclitaxel (60 mg/m2) and carboplatin 
at a dose AUC 2 administered weekly showed lower 
toxicity with comparable effectiveness, and it seems to 
be worth considering in older patients or in those with 
poorer performance status [22].
In the group of patients at stage III with residual 
tumour of over 1 cm, in patients at stage IV, and not 
operated the treatment with bevacizumab at a dose 
of 7.5 mg/kg combined with standard chemotherapy 
(paclitaxel 175 mg/m2 and carboplatin AUC 5–7.5) 
with subsequent maintenance treatment (bevacizumab 
alone) up to a total of 18 applications significantly 
prolongs progression-free survival (PFS) and overall 
survival (OS). Currently in Poland this treatment is part 
of the therapeutic drug program (Table 2).
Development of hypersensitivity reactions to pacli-
taxel is an indication to consider its replacement with 
docetaxel [23].
Neoadjuvant chemotherapy
When primary cytoreduction in patients at FIGO 
stages III and IV is impossible, a reasonable option is 
to use an initial, neoadjuvant chemotherapy according 
to standard paclitaxel- and carboplatin-based protocol. 
Patients eligible for this treatment have histologically or 
cytologically confirmed ovarian cancer, adnexal tumour, 
and a CA-125/CEA ratio of 25:1 (20% of patients with 
clinical signs of ovarian cancer may harbour another 
tumour, e.g. gastrointestinal or breast cancer). The 
results obtained are similar to those seen in the group 
undergoing primary non-optimal cytoreduction, while 
perioperative mortality is significantly lower. After three 
Table 2. Options of first-line chemotherapy in cancer of the ovary, depending on the clinical stage of the disease
FIGO stage Chemotherapy protocol 
I A/B G1  Follow-up* 
I A/B G2 and G3/C Paclitaxel at a dose of 175 mg/m2 IV (3-hours’ infusion) on day 1 + carboplatin AUC 5–7 IV  
(1-hour’ infusion) on day 1, every 21 days, 3–6 cycles [18, 24] 
II–IV  
standard 
Paclitaxel at a dose of 175 mg/m2 IV (3-hours’ infusion) on day 1 + carboplatin AUC 5–7.5 IV  
(1-hour’ infusion) on day 1, every 21 days, 6 cycles [18]
II–IV 
alternatives 
Paclitaxel at a dose of 135 mg/m2 IV (24-hours’ infusion) on day 1 + cisplatin at a dose of 
75 mg/m2 IV on day 2 [19] 
or 
Paclitaxel at a dose of 80 mg/m2 IV (1-hour’ infusion) on days 1, 8 and 15 + carboplatin AUC 6 IV 
(1-hour’ infusion) on day 1, every 21 days, 6 cycles [21] 
or 
Paclitaxel at a dose of 60 mg/m2 IV (1-hour’ infusion) + carboplatin AUC 2 IV (30-min’ infusion) every 
7 days, 18 cycles [22]
or
Docetaxel at a dose of 60–75 mg/m2 IV (1-hour’ infusion) on day 1 + carboplatin IV AUC 5–6  
(1-hour’ infusion) on day 1, every 21 days, 6 cycles [23]
II–IV with residual 
tumour < 1 cm 
Paclitaxel at a dose of 135 mg/m2 IV (24-hours’ infusion) on day 1 + cisplatin at a dose  
of 75–100 mg/m2 IP on day 2 + paclitaxel at a dose of 60 mg/m2 IP on day 8, every 21 days, 6 cycles [20] 
III–IV with residual 
tumour > 1 cm 
Paclitaxel at a dose of 175 mg/m2 IV (3-hours’ infusion) on day 1 + carboplatin AUC 5–7.5 IV  
(1-hour’ infusion) on day 1, every 21 days + bevacizumab at a dose of 7.5 mg/kg body weight every 
21 days starting on days 1 or 2 of chemotherapy (up to 18 applications)** [22]
*Possible only in cases of correctly performed surgical staging; clear-cell type is considered G3.
**Polish program of therapy with bevacizumab requires indicating the size of gross residual disease in the operation’s protocol and performing computed 
tomography after the operation, in order to qualify the patients to the treatment.
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courses, performance of an IDC should be considered. 
Use of neoadjuvant chemotherapy in other clinical set-
tings is hardly justified [25, 26]. 
Consolidation treatment 
Systemic consolidation treatment in patients with 
complete remission after first-line chemotherapy, de-
spite its proven efficacy [27], has not become everyday 
clinical practice.
Assessment of treatment outcome 
Treatment outcomes should be evaluated four weeks 
after completion of first-line chemotherapy. For this 
purpose, the following studies should be done:
 — medical history and physical examination;
 — gynaecological vaginal and rectal examination, in-
cluding vaginal specula;
 — transvaginal and abdominal sonography;
 — basic laboratory tests of blood and urine;
 — assessment of serum level of antigens monitored 
during treatment;
 — chest X-ray or CT-scan;
 — pelvic and abdominal CT-scan. 
Outcome assessment by imaging studies should be 
based on RECIST 1.1 criteria (Appendix 3).
Follow-up 
Patients obtaining complete clinical remission 
should undergo systematic control. Follow-up exams 
should be performed every three months for two years 
after completion of treatment, then every six months 
for five years after completion of treatment, and then 
every 12 months. Follow-up examination should include 
medical history and clinical examination. 
Routine assessment of CA-125 during follow-up 
should be discussed with the patient. Resumption of 
treatment solely based on clinical symptoms does not 
worsen final outcome in terms of overall survival [28]. 
Implementation of second-line chemotherapy based 
solely on elevated CA-125 is not justified; it does not im-
prove survival but considerably compromises its quality. 
Imaging studies are obtained only in the case of 
suspected recurrence.
Treatment of recurrence 
Considering current state-of-the-art of surgery and 
chemotherapy, cancer of the ovary becomes a chronic 
disease for most patients. Time from diagnosis to recur-
rence is now shorter than time from recurrence to death. 
For most ovarian cancer patients, the disease constitutes 
a continuum of alternating episodes of recurrence in-
terspaced with increasingly short symptom-free periods, 
ending in a phase of lack of response to cytostatics. 
Incurability of major cases of tumour recurrence 
results in a modification of treatment strategy. In such 
cases the treatment goals are as follows:
 — alleviation of symptoms;
 — improvement of quality of life;
 — delay of symptomatic tumour progression;
 — prolongation of survival. 
Objective therapeutic response is not the primary goal. 
The main modality in the treatment of recurrence of ovar-
ian cancer is palliative chemotherapy, but in selected cases 
a resective surgery should be considered, which may affect 
significantly the survival time in about 10% of patients [29]. 
Surgical treatment of recurrence
A significant impact on prolongation of survival is seen 
only in procedures resulting in total gross cytoreduction. 
Proper selection of patients is paramount. The results of 
many studies indicate that surgical treatment of recurrence 
is justified if primary surgery led to complete resection, 
recurrence occurred more than 12 months after comple-
tion of first-line chemotherapy, there is no ascites, and 
the recurrent lesion is potentially completely resectable, 
most often defined as isolated. There are three available 
recommendations for selection of patients (Appendix 4).
Use of AGO score [30] enables selection of patients 
where total cytoreduction will be obtained in 2 out of 
3 cases. AGO score includes:
 — good performance status (grade 0 in Eastern Coop-
erative Oncology Group scale);
 — total resection during primary surgery;
 — no fluid in abdominal cavity. 
Chemotherapy of recurrence
Selection of second-line chemotherapy protocol is 
based on sensitivity to platinum derivates, which defines 
prognosis. The effect of first-line treatment and time 
elapsing since completion of first-line treatment define 
the categories of patients [31]:
 — platinum non-sensitive — tumour progression dur-
ing first-line treatment (5.3% of patients);
 — platinum resistant — recurrence within six months 
after completion of first-line treatment (17.2% 
of patients);
 — partly platinum sensitive — recurrence within 
6–12 months after completion of first-line treatment 
(22.7% patients);
 — platinum sensitive — recurrence after more than 
12 months since completion of first-line treatment 
(33.5% of patients) [32].
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In 3.7% of patients recurrence develops between 
60 and 120 months after completion of first-line treat-
ment. 
The prognosis in patients resistant to platinum 
derivates is poor. The rate of response to second-line 
chemotherapy usually does not exceed 10–15%, and the 
mean time to progression is about three months. In this 
group, no clinical benefit of multi-agent chemotherapy 
compare to single-agent regimens could be demon-
strated (Table 3). A combination of cytostatics with 
bevacizumab significantly improved PFS (which is as 
twice as long as in the group not receiving bevacizumab). 
Treatment should be offered to selected patients only, in 
good performance status, without significant persistent 
complications, and motivated for treatment. 
Treatment of platinum-sensitive recurrence, re-in-
duction using platinum-based multi-agent protocols 
(selection of protocol should take into account expected 
toxicity of treatment) is more effective than platinum in 
monotherapy. Response rate increases proportionally 
to PFS and ranges from 29 to 70%. 
Treatment of recurrence (both platinum-sensitive 
and platinum-resistant), addition of bevacizumab to che-
motherapy, and subsequent administration of this agent 
in monotherapy until disease progression prolongs PFS. 
No prolongation of overall survival has been observed. 
In the case of achieving an objective response 
(partial or complete) in patients with low-grade serous 
subtype of ovarian cancer with mutations of BRCA1 and 
BRCE2 genes (germinal and/or somatic) after treatment 
of platinum-sensitive recurrence with platinum derivates 
using olaparib during maintenance therapy should be 
considered, which significantly prolongs time to progres-
sion. The effect of olaparib on overall survival is yet to 
be published [10, 43].
Response to second-line and subsequent lines of 
chemotherapy should be monitored using CA-125 bio-
marker and imaging studies. Lack of response to two 
lines of treatment should result in interruption of 
chemotherapy. 
Palliative procedures are performed most often 
in the setting of ileus. In some patients they result in 
transient alleviation of symptoms. The impact of such 
procedures on prolongation of survival is limited. 
Radiotherapy 
Use of radiotherapy is limited to the treatment of 
focal lesions (brain and bone metastases). 
Borderline tumours 
In 1971 (FIGO) and in 1973 (World Health Organi-
sation, WHO) a group of cancers of the ovary were 
selected and defined as low malignant potential/bor-
derline tumours. These tumours account for about 15% 
of epithelial cancers of the ovary and in 60–90% are 
unilateral only. Nearly two thirds of borderline ovar-
ian tumours are of serous histology and the remaining 
are mucinous. 
A characteristic feature of borderline tumours, par-
ticularly serous and mucinous of the cervical type, is the 
coexistence of implants in peritoneum and omentum, 
which may be noninvasive (90%) or invasive (10%). 
Borderline tumours of the ovary usually develop in 
women of reproductive age; the mean age at diagnosis 
is 38–45 years. 
Basic diagnostic criterion for borderline tumours is 
lack of destructive stromal invasion (according to the 
WHO) [44]. 
Clinical staging 
This is done according the same FIGO classification 
criteria as those pertaining to ovarian cancer. 
Table 3. Second-line chemotherapy depending on type of response to platinum
Response to platinum derivatives Chemotherapy 
Primary non-sensitive (refractory) 
Platinum-resistant (resistance) 




paclitaxel every 7 days [37]
liposomal doxorubicin or topotecan, or paclitaxel every 7 days + bevacizumab [38]
Partly platinum-sensitive 
Platinum-sensitive 
Paclitaxel + carboplatin/cisplatin [39]
Gemcitabine + carboplatin/cisplatin [40]
Carboplatin + liposomal doxorubicin [41]
Gemcitabine + carboplatin + bevacizumab [42]
Carboplatin in monotherapy 
239
Antoni Basta et al., Recommendation of the Polish Society of Oncological Gynaecology on the diagnosis and treatment of epithelial ovarian cancer
www.opk.viamedica.pl
Treatment of borderline tumours 
The cornerstone of treatment of borderline ovarian 
tumours is surgery. 
Early clinical stages (I and II)
When the patient wants to preserve fertility (age 
under 40 years):
 — at stage IA, scope of surgery includes: oopho-
rectomy, detailed inspection of the pelvis and 
abdominal cavity, peritoneal lavage, and biopsy 
of the other ovary if grossly abnormal. Mucinous 
type requires appendectomy and excision of the 
entire ovary and not just enucleation of the tumour 
because this histology type is more frequently 
connected with recurrence. Intraoperative study 
may be unreliable (no entire tumour capsule is 
available for study). At stage IB, when tumours 
are present in both ovaries, unilateral enuclea-
tion of tumour is justified (considered as better 
delimited). Some authors accept enucleation of 
both tumours [45, 46].
When the patient does not want to preserve fertility:
 — stages I and II: recommended total hysterectomy 
with oophorosalpingectomy, omentectomy, and 
staging of the disease. Only enlarged lymph nodes 
should be excised. There is no proven improvement 
after systemic lymphadenectomy;
 — stages III and IV: surgical treatment is recom-
mended, aiming at total cytoreduction. 
Chemotherapy of borderline tumours
Adjuvant platinum-based chemotherapy is not 
currently recommended in patients after operation of 
borderline tumours with detected invasive implants, 
because the results of reports published to date show no 
significant decrease in the recurrence risk or mortality 
after such a treatment [47].
Postoperative chemotherapy does not prolong sur-
vival and is not recommended [48].
Follow-up 
Similarly to invasive cancers, patients should be 
monitored. This is particularly important in patients 
undergoing sparing surgery. There are no data justifying 
excision of spared ovary and uterus after giving birth to 
a planned number of children.
Recurrences of borderline tumours
They are a rare phenomenon and occur in about 
7.8% of the patients. In approximately 30% of patients 
recurrent borderline tumours transform into ovarian 
cancer. The recurrences are significantly more frequent 
in the following cases:
 — presence of residual tumour after primary surgery;
 — presence of invasive implants;
 — sparing procedure;
 — inadequate determination of clinical stage [47].
The authors would like to thank Ms. Renata Buda, 
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APPENDIX 1
RMI (risk of malignancy index)
RMI=U × M × CA-125
Feature Description Score of the feature
CA-125 level Serum concentration Value in U/ml
USG index Receives 1 point for each of the feature of ovarian tumour:
— multilocular cyst
— solid components
— presence of implants/metastases
— pelvis fluid
— bilateral ovarian lesions
U = 0 (when score value of USG index is 0)
U = 1 (when score value of USG index is 1)
U = 3 (for all higher values, e.g. 2–5)
Menopausal state Definition of menopauses: amenorrhea since ≥ 1 year or 
patients after hysterectomy and at the age of more than 
50 years
M = 1 point, if patient is before menopause, or
M = 3 points, if patient is after menopause
Ultrasonography index “U” is calculated adding points for features (1 point for each).
Parameter “U” could have the value:
U = 0 (number of points: 0);
U = 1 (number of points: 1);
or U = 3 (number of points: 2–5)
Patients are considered to be after menopause if they had no menorrhoea for more than 1 year or are women who are more than 50 years old and have 
undergone hysterectomy.
APPENDIX 2
Cancer of ovary, fallopian tube and peritoneum: current staging according to FIOGO classification (version 2014); stage I
FIGO classification, version 1988 FIGO classification, version 2014 (*)
Stage I: Tumour limited to ovary Stage I: Tumour limited to ovary or fallopian tube
IA Tumour limited to 1 ovary, capsule intact, no tumour on 
surface, negative washings/ascites
IA Tumour limited to 1 ovary or fallopian tube, capsule 
intact, no tumour on surface of ovary or fallopian tube, 
negative washings/ascites
IB Tumour involves both ovaries, capsule intact, no tumour 
on surface, negative washings/ascites
IB Tumour involves both ovaries or fallopian tubes, capsule 
intact, no tumour on surface of ovary or fallopian tube, 
negative washings/ascites
IC Tumour involves 1 or both ovaries with any of the 
following: capsule rupture, tumour on surface, positive 
washings/ascites
IC Tumour limited to 1 or both ovaries or both fallopian 
tubes with:
IC1 Surgical spill
IC2 Capsule rupture before surgery or tumour on ovarian or 
fallopian tube surface
IC3 Malignant cells in the ascites or peritoneal washings
*Changes marked with italics
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Cancer of ovary, fallopian tube, and peritoneum: current staging according to FIOGO classification (version 2014); stage II
FIGO classification, version 1988 FIGO classification, version 2014 (*)
Stage II: Tumour involves 1 or both ovaries with pelvic 
extension
Stage II: Tumour involves 1 or both ovaries or fallopian 
tubes with pelvic extension (below the pelvic brim) or 
primary peritoneal cancer
IIA Extension and/or implant on uterus and/or fallopian 
tube/tubes, negative washings/ascites
IIA Extension and/or implant on uterus and/or fallopian 
tube/tubes
IIB Extension to other pelvic intraperitoneal tissues, negative 
washings/ascites
IIB Extension to other pelvic intraperitoneal tissues
IIC Extension to other pelvic intraperitoneal tissues (IIA or IIB) 
with positive washings/ascites
*Changes marked with italics
Cancer of ovary, fallopian tube, and peritoneum: current staging according to FIOGO classification (version 2014); stage III
FIGO classification, version 1988 FIGO classification, version 2014 (*)
Stage III: Tumour involves 1 or both ovaries with 
cytologically or histologically confirmed spread to  
the peritoneum outside the pelvis and/or metastasis  
to the regional lymph nodes
Stage III: Tumour involves 1 or both ovaries or fallopian 
tube/tubes, or primary peritoneal cancer with spread to 
the peritoneum outside the pelvis and/or metastasis to 
the regional retroperitoneal lymph nodes
IIIA Microscopic metastasis to the peritoneum beyond 
the pelvis
IIIA1 Cancer metastases only to the retroperitoneal lymph 
nodes (cytologically or histologically confirmed)
IIIA1(i) Metastases with the greatest size ≤ 10 mm 
IIIA1(ii) Metastases with the greatest size > 10 mm
IIIA2 Microscopic, extrapelvic (above the brim) peritoneal 
involvement ± positive retroperitoneal lymph nodes
IIIB Macroscopic, extrapelvic, peritoneal 
metastasis ≤ 2 cm in greatest dimension
IIIB Macroscopic, extrapelvic, peritoneal 
metastasis ≤ 2 cm ± positive retroperitoneal lymph 
nodes, including extension to capsule of liver/spleen 
(with no lesions in parenchyma) 
IIIC Macroscopic, extrapelvic, peritoneal 
metastasis > 2 cm in greatest dimension and/or 
regional lymph node metastasis
IIIC Macroscopic, extrapelvic, peritoneal 
metastasis > 2 cm ± positive retroperitoneal lymph 
nodes, including extension to capsule of liver/spleen 
(with no lesions in parenchyma)
*Changes marked with italics
Cancer of ovary, fallopian tube, and peritoneum: current staging according to FIOGO classification (version 2014); stage IV
FIGO classification, version 1988 FIGO classification, version 2014 (*)
Stage IV: Distant metastasis (excluding peritoneal 
metastasis)
Stage IV: Distant metastasis (excluding peritoneal 
metastasis)
IV Distant metastasis (excluding peritoneal metastasis) IVA Pleural effusion with positive cytology
IVB Hepatic and/or splenic parenchymal metastases, 
metastases to extra-abdominal organs (including 
inguinal lymph nodes and lymph nodes outside of the 
abdominal cavity)
*Changes marked with italics
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Patients’ status is qualified as:
— Complete Response (CR): disappearance of all target lesions. Shrinkage of any pathological lymph nodes (whether target or non-
target) in short axis to < 10 mm (RECIST 1.1). Parallel biochemical normalization
— Partial Response (PR): shrinkage of at least a 30% of tumour or the sum of diameters of target lesion, taking as reference the 
baseline sum diameters
— Stable Disease (SD): neither shrinkage of less than 30% of tumour or the sum of diameters of target lesions or increase of less 
than 20% of tumour or the sum of diameters of target lesion
— Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum 
in the study (absolute increase of at least 5 mm) and/or appearance of one or more new lesions
APPENDIX 4
Recommendations concerning second-line cytoreduction surgery 
A. Recommendations of Norwegian Radium Hospital [29] 
Disease-free survival (months) Localised disease Disseminated disease 
0–5 Consider Do not perform 
6–11 Suggest Do not perform 
12–23 Suggest Do not perform 
> 24 Suggest Consider 
B. Memorial Sloan-Kettering Cancer Centre [48]
Disease-free survival (months) Localised disease Disseminated disease Peritoneal cancer spread 
6–12 Suggest Consider Do not perform 
12–30 Suggest Suggest Consider 
> 30 Suggest Suggest Suggest 
C. Onda [48] 
Patient should fulfil at least 3 out of 4 criteria:
— disease-free survival > 12 months
— no metastases to the liver
— isolated lesion
— tumour size < 6 cm
